Breckenridge secures marketing agreement with Gland Pharma for 7 injectables

By Melissa Fassbender contact

- Last updated on GMT

The injectable products cover a range of indications. (Image: iStock/Mckyartstudio)
The injectable products cover a range of indications. (Image: iStock/Mckyartstudio)

Related tags: Pharmaceutical drug, Pharmacology

Breckenridge Pharmaceutical has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven injectable products.

Per the agreement, Breckenridge will market and distribute six approved ANDAs and one tentatively-approved ANDA under its label in the United States.

Breckenridge announced its entry into the injectable market​ in November with the launch of Methylergonovine Maleate Injection. The company commented at the time that the launch was “the first of several planned injectable products​” expected in the near future.

The company also announced a license to market Armodafinil​ tablets – a generic version of Nuvigil® by Cephalon – in partnership with Natco Pharma Limited.

Related news

Show more

Related products

Keys To A Successful Rapid Commercial Launch

Keys To A Successful Rapid Commercial Launch

Catalent Pharma Solutions | 21-Oct-2020 | Insight Guide

Pharma and biotech companies are dedicating resources to new treatments with the hope of helping patients. The quicker they can get products to patients,...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q² Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Related suppliers

Follow us

Products

View more

Webinars